Scientific Materials :: IMV Inc. (IMV)

AACR, April 2023

An immune-educating therapy, maveropepimut-S, elicits a diverse and active anti-tumor T cell response in patients with advanced recurrent ovarian cancer

Society of Gynecologic Oncology, 2023 Annual Meeting on Women’s Cancer, March 2023

Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer

Immuno-Oncology 360° Conference, February 2023

Delivery Matters: Leveraging the DPX Cancer Vaccine Platform to Educate Sustained Anti-cancer Immunity and Durable Clinical Benefit

San Antony Breast Cancer Symposium (SABCS), December 2022

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC).

SITC, November 2022

DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens

SITC, November 2022

Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab

SITC, November 2022

Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)

CRI-ENCI-AACR, September 2022

Cancer-associated fibroblasts as a negative predictor of response to maveropepimut-S, a novel immune educating therapy, in patients with advanced, recurrent ovarian cancer in the DeCidE1 phase 2 trial

RIVKIN - AACR VIRTUAL OVARIAN CANCER RESEARCH SEMINAR SERIES, SEPTEMBER 2022

Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a single-arm phase II trial